Misuse of Ozempic as a drug choice for weight loss, a potential threat
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20233563Keywords:
Ozempic, Weight loss, Diabetes mellitusAbstract
The 387 million people around the globe are diagnosed with type 2 diabetes mellitus (T2DM). Previously used agents to treat T2DM posed adverse risks of hypoglycaemia and weight gain. Recently, Novo Nordisk, a pharmaceutical company, launched a new drug, Ozempic (Semaglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which was approved by the US Food and Drug Administration on December 5, 2017. The numerous benefits of Ozempic makes it ideal for treatment of T2DM. Unfortunately, there is now an alarming shortage of Ozempic due to its misuse for weight loss.
Metrics
References
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context. 2015;4:212283.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular metabolism. 2021;46:101102.
Victor N. Ozempic. 2023. Available at: https://www.medicalnewstoday.com/articles/326252. Accessed on 15 November, 2023.
Oceane D, Natalie H. Ozempic: How a TikTok weight loss trend caused a global diabetes drug shortage - and health concerns. 2023. Available at: https://www.euronews.com/next/2023/03/02/ozempic-how-a-tiktok-weight-loss-trend-caused-a-global-diabetes-drug-shortage-and-health-c. Accessed on 15 November, 2023.
